Breakthrough VAXINIA Technology Presented at Cholangiocarcinoma Conference

Imugene Limited (ASX: IMU) announces the selection of its CF33-hNIS (VAXINIA) technology for oral and poster presentations at the 2024 Cholangiocarcinoma Foundation Annual Conference in Sydney, Australia. The presentation, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies,’ emphasizes the potential of CF33-hNIS monotherapy as a safe and effective treatment for gastrointestinal malignancies, including cholangiocarcinoma.

The conference, dedicated to advancing understanding and treatment of bile duct cancer, serves as a vital platform for medical professionals, researchers, patients, and caregivers to exchange insights and advancements in research and patient care. Cholangiocarcinoma, a rare and aggressive cancer, poses significant challenges in early detection and treatment, underscoring the importance of ongoing research and innovation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com